You are here:
rivaroxaban (Xarelto) atrial
Advice
Following a full submission:
rivaroxaban (Xarelto®) is accepted for restricted use within NHS Scotland.
Indication under review: the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
SMC restriction: Rivaroxaban is accepted for use in patients who have poor INR control despite evidence that they are complying with a coumarin anticoagulant and in patients who are allergic to or unable to tolerate coumarin anticoagulants.
Rivaroxaban was non-inferior to standard oral anticoagulation at preventing stroke or systemic embolism in one large, double-blind study in patients with atrial fibrillation and moderate to high risk of stroke. This was not associated with a significantly increased risk of major or non-major clinically relevant bleeding.
The submitting company made an economic case for rivaroxaban use in the restricted patient population described above.
Drug Details
| Drug Name: | rivaroxaban (Xarelto) atrial |
|---|---|
| SMC Drug ID: | 756/12 |
| Manufacturer: | Bayer plc/Bayer Schering Pharma |
| Indication: | For atrial fibrillation |
| BNF Category: | |
| Sub Category: | 2.8 Anticoagulants and protamine |
| Submission Type: | Full submission |
| Status: | Restricted |
| Date Advice Published: | 13 February 2012 |